ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 530,72
-1,03%
Dow Jones
39 164,06
0,09%
DAX
18 210,55
0,26%
Brent Oil
85,255
0,93%
Bitcoin
61 416,34
0,99%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Atara Biotherapeutics Inc (ATRA)

  7. Atara Biotherapeutics Inc (ATRA) Actualités

ATRA

Atara Biotherapeutics (ATRA)

Atara Biotherapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ATRA
DateHeureSourceTitreSymboleSociété
21/06/202422h01Business WireAtara Biotherapeutics’ Ebvallo™ (tabelecleucel) Wins Prix Galien International Award for Best Product for Orphan/Rare DiseasesNASDAQ:ATRAAtara Biotherapeutics Inc
17/06/202414h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATRAAtara Biotherapeutics Inc
17/06/202414h00Business WireAtara Biotherapeutics Announces 1-for-25 Reverse Stock SplitNASDAQ:ATRAAtara Biotherapeutics Inc
11/06/202423h06Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ATRAAtara Biotherapeutics Inc
07/06/202422h01Business WireAtara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ATRAAtara Biotherapeutics Inc
05/06/202422h01Business WireAtara Biotherapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:ATRAAtara Biotherapeutics Inc
29/05/202422h01Business WireAtara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual MeetingNASDAQ:ATRAAtara Biotherapeutics Inc
23/05/202400h18Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:ATRAAtara Biotherapeutics Inc
21/05/202402h34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ATRAAtara Biotherapeutics Inc
20/05/202415h25Business WireAtara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDANASDAQ:ATRAAtara Biotherapeutics Inc
17/05/202403h15Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ATRAAtara Biotherapeutics Inc
10/05/202422h30Edgar (US Regulatory)Form DEFR14A - Revised definitive proxy soliciting materialsNASDAQ:ATRAAtara Biotherapeutics Inc
09/05/202422h11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ATRAAtara Biotherapeutics Inc
09/05/202422h01Business WireAtara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational ProgressNASDAQ:ATRAAtara Biotherapeutics Inc
28/03/202413h30Business WireAtara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational ProgressNASDAQ:ATRAAtara Biotherapeutics Inc
29/02/202415h05Business WireAtara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T TherapyNASDAQ:ATRAAtara Biotherapeutics Inc
28/02/202422h30Business WireAtara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care ConferenceNASDAQ:ATRAAtara Biotherapeutics Inc
14/02/202415h00Business WireAtara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus NephritisNASDAQ:ATRAAtara Biotherapeutics Inc
01/02/202408h25PR Newswire (US)Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet OncologyNASDAQ:ATRAAtara Biotherapeutics Inc
09/01/202422h28Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ATRAAtara Biotherapeutics Inc
08/01/202415h00Business WireAtara Biotherapeutics Announces $15 Million Registered Direct OfferingNASDAQ:ATRAAtara Biotherapeutics Inc
08/01/202414h00Business WireAtara Biotherapeutics to Present Recent Progress and Key Upcoming Milestones at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ATRAAtara Biotherapeutics Inc
04/01/202422h01Business WireAtara Biotherapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ATRAAtara Biotherapeutics Inc
20/12/202322h01Business WireAtara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre LaboratoriesNASDAQ:ATRAAtara Biotherapeutics Inc
11/12/202318h00Business WireAtara Biotherapeutics Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual MeetingNASDAQ:ATRAAtara Biotherapeutics Inc
01/12/202322h01Business WireAtara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ATRAAtara Biotherapeutics Inc
30/11/202300h05Business WireAtara Biotherapeutics To Present Positive New Tab-cel® Clinical Data During Oral Session at ESMO Immuno-Oncology Annual Congress 2023NASDAQ:ATRAAtara Biotherapeutics Inc
22/11/202322h01Business WireAtara Biotherapeutics to Participate at the 6th Annual Evercore ISI HealthCONx ConferenceNASDAQ:ATRAAtara Biotherapeutics Inc
17/11/202322h31Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ATRAAtara Biotherapeutics Inc
14/11/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ATRAAtara Biotherapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ATRA

Dernières Valeurs Consultées

BIT
P217I8
NLBNPIT217I8 20991231 5....
BIT
UC2E0U
Unicredit Bank
BIT
F19831
Vontobel Financial Produ...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés